(Pleconaril + ribavirin) is under clinical development by Apodemus and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Pleconaril + ribavirin)’s likelihood of approval (LoA) and phase transition for Type 1 Diabetes (Juvenile Diabetes) took place on 09 Apr 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Pleconaril + ribavirin) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Pleconaril + ribavirin) overview

Apovir (a fixed dose combination of pleconaril and ribavirin) is under development for the treatment of type 1 diabetes due to chronic viral infections. It is formulated as a liquid and capsule and is administered through oral route. It was also under development for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.

Apodemus overview

Apodemus is a pharmaceutical company that develops antiviral treatments and diagnostic tools for viral infections. The company performs PCR-based diagnostics with next generation sequencing and immunological methods to identify the presence of virus in samples of different origin. Its research and development portfolio comprise several projects in different stages of development. Apodemus also conducts clinical trial in Alzheimer´s diseases where the patients are treated with antivirals. The company develops tools for patient diagnosis and techniques for genetic mapping of disease causing viral strains. Apodemus is headquartered in Solna, Sweden.

Quick View (Pleconaril + ribavirin) LOA Data

Report Segments
  • Innovator
Drug Name
  • (Pleconaril + ribavirin)
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.